MAY 08, 2018 10:27 PM PDT

Developing a Drug For Genetic Obesity

WRITTEN BY: Nouran Amin

Researchers from the Institute for Experimental Pediatric Endocrinology of the Charité -- Universitätsmedizin Berlin have fortunately treated patients with genetic obesity using a recent developed drug.

Genetic obesity is obesity caused by a mutation in one or multiple genes that have a relation fat storage and hunger. Aside from its beneficial effects on the patients, the researchers also provided insights into the fundamental signaling pathways regulating satiety of the new drug. The results of this research were published in Nature Medicine.

In this study, a mutation in the gene encoding the leptin receptor (LEPR) leads to extreme hunger starting with the first months of life. As a result, individuals affected developed extreme obesity during childhood. However, for these cases, increased exercise and reduced caloric intake are still not relevant as well as obesity surgery. This explains why a drug-based approach remains a priority.

Furthermore, roughly two years before the study, Dr. Peter Kühnen and team demonstrated that treatment with a peptide, which works to activate the melanocortin 4 receptor (MC4R) that may have a role in energy metabolism in the body as well as body weight regulation.

Leptin, which is known as the satiety (or starvation) hormone, will normally bind to the leptin receptor (LEPR) which then leads to the production of melanocyte-stimulating hormone (MSH). However, if there exists a mutation in LEPR that leads to a functional defect then the signaling cascade is disrupted. This allows the patient's hunger to continue to be unabated, placing the individual at a high risk.

Part of this current study, investigators used a peptide that binds to the MC4R in the brain, and through this activation, it will trigger the normal satiety signal. "We also wanted to determine why the used peptide was so effective and why, in contrast to other preparations with a similar mode of action, it did not produce any severe side effects," explains Dr. Kühnen. "We were able to demonstrate that this treatment leads to the activation of a specific and important signaling pathway, whose significance had previously been underestimated." Dr. Kühnen's team is planning to conduct further research to determine whether other patients might benefit from this drug: "It is possible that other groups of patients with dysfunctions affecting the same signaling pathway might be suitable candidates for this treatment."

 

Sources: Charité - Universitätsmedizin Berlin

 

 

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
NOV 27, 2019
Drug Discovery & Development
NOV 27, 2019
New Painkiller More Effective than Opioids Discovered in Mud
Researchers have discovered a new painkiller dubbed to be as effective as opioids, only minus their disadvantages, from a 16-year old mud sample found near...
DEC 21, 2019
Drug Discovery & Development
DEC 21, 2019
Improving Vaccines for Meningitis
Scientists at the University of Nottingham are seeking new ways to improve vaccine use in the protection against the bacterium, Neisseria meningitides that...
DEC 22, 2019
Drug Discovery & Development
DEC 22, 2019
Effective Therapeutic Approved for Migraines
The U.S Food and Drug Administration has now approved a new medication for migraines. The drug is called ‘ubrogepant (Ubrelvy)’ and comes in th...
JAN 03, 2020
Drug Discovery & Development
JAN 03, 2020
Researchers Grow Psilocybin from E. Coli Bacteria
Previously considered to be narcotic, and under tight regulation as an illicit drug for decades, research from recent years on the possible medicinal prope...
JAN 06, 2020
Drug Discovery & Development
JAN 06, 2020
Designing Drugs To Fight off C. Diff Infections
A study published by PNAS explains breakthrough research around designing drugs that target C. diff bacterial infections that result in 15,000 deaths in th...
JAN 22, 2020
Cannabis Sciences
JAN 22, 2020
Antibiotic Properties Found in Cannabis Compound
The World Health Organization has identified antibiotic resistance, when bacteria no longer respond to antibiotics, as one of the biggest threats to global...
Loading Comments...